Key facts
- This page summarizes Daniel J. Curran's Form 3 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Aug 2025, 17:00.
Daniel J. Curran - 01 Aug 2025 Form 3 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)
- Reporting relationship
- Director
- Issuer ticker
- CPRX
- Reported as of
- 01 Aug 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Aug 2025, 17:00:08 UTC
- Prior SEC filing
- 12 Jun 2025
- Next SEC filing
- 13 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel J. Curran
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel J. Curran filed Form 3 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 08 Aug 2025.
Change
- Previous filing in this sequence was filed on 12 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001887599
Primary reporting owner
Curran Daniel J.
- Relationship
- Director
- Address
- 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES
- Signature
- /s/ Daniel J. Curran
- Signature date
- 08 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CPRX
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 01 Aug 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CPRX
holding
Derivative
Options to purchase common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $21.12
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Options vest in three annual tranches beginning on August 1, 2026.